ANGPTL3 and metabolic dysfunction-associated steatotic liver disease: Consistent with these results, C44-Fc, as an ANGPTL3 inhibitor, showed remarkable potency in lowering lipid and therapeutic effect on NAFLD in mice model, and was likely to be a prospective therapeutic agent for hypercholesterolemic and NAFLD patients.